• 1
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993; 329: 97786.
  • 2
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 83751.
  • 3
    Geistanger A, Arends S, Berding C et al. Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden. Clin Chem. 2008; 54: 137985.
  • 4
    International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. [see comment]. Diabetes Care. 2009; 32: 132734.
  • 5
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2010; 33: S1161.
  • 6
    Little RR, Rohlfing CL, Sacks DB, for the National Glycohemoglobin Standardization Program Steering C. Status of hemoglobin A1c measurement and goals for improvement: from Chaos to order for improving diabetes care. Clin Chem. DOI: 2010.148841.
  • 7
    College of American Pathologists. Surveys 2010 GH2-A Glycohemoglobin Participant Summary. Vol. College of American Pathologists, Nothfield (IL), 2010.
  • 8
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193203.
  • 9
    National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. Available from: (Accessed September 2010).
  • 10
    Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989; 27: 40937.
  • 11
    Rohlfing C, Wiedmeyer HM, Little R et al. Biological variation of glycohemoglobin. Clin Chem. 2002; 48: 11168.
  • 12
    Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int. 1999; 41: 35762.
  • 13
    Little RR, Rohlfing CL, Hanson S et al. Effects of hemoglobin (Hb) E and HbD traits on measurements of glycated Hb (HbA1c) by 23 methods. Clin Chem. 2008; 54: 127782.
  • 14
    Mongia SK, Little RR, Rohlfing CL et al. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays. Am J Clin Pathol. 2008; 130: 13640.
  • 15
    Rohlfing CL, Connolly SM, England JD et al. The effect of elevated fetal hemoglobin on hemoglobin A1c results: five common hemoglobin A1c methods compared with the IFCC reference method. Am J Clin Pathol. 2008; 129: 8114.
  • 16
    NGSP. HbA1c assay interferences. Available from: (accessed November, 2010).
  • 17
    Pani LN, Korenda L, Meigs JB et al. Effect of aging on A1c levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes Care. 2008; 31: 19916.
  • 18
    Herman WH, Ma Y, Uwaifo G et al. Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007; 30: 24537.
  • 19
    Herman WH, Dungan KM, Wolffenbuttel BH et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94: 168994.